TherapeuticsMD (TXMD) to Release Earnings on Monday

TherapeuticsMD (NASDAQ:TXMD) is anticipated to release its Q1 2026 results before the market opens on Monday, May 18th. Analysts expect TherapeuticsMD to post earnings of ($6.1250) per share and revenue of $19.7680 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 19, 2026 at 4:00 PM ET.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($6.12) by $6.07. The business had revenue of $0.89 million during the quarter, compared to the consensus estimate of $19.77 million. TherapeuticsMD had a negative net margin of 18.83% and a negative return on equity of 2.41%.

TherapeuticsMD Price Performance

TherapeuticsMD stock opened at $1.98 on Monday. The company has a market capitalization of $22.91 million, a PE ratio of -198.00 and a beta of 0.58. The firm has a fifty day simple moving average of $2.15 and a two-hundred day simple moving average of $1.95. TherapeuticsMD has a twelve month low of $0.98 and a twelve month high of $2.95.

Hedge Funds Weigh In On TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Renaissance Technologies LLC raised its position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 171.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 96,500 shares of the company’s stock after acquiring an additional 61,000 shares during the quarter. Renaissance Technologies LLC owned approximately 0.83% of TherapeuticsMD worth $157,000 at the end of the most recent quarter. 30.74% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of TherapeuticsMD from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Monday, April 6th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.